369 related articles for article (PubMed ID: 22644934)
1. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Krishnan B; Torti FM; Gallagher PE; Tallant EA
Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Krishnan B; Smith TL; Dubey P; Zapadka ME; Torti FM; Willingham MC; Tallant EA; Gallagher PE
Prostate; 2013 Jan; 73(1):71-82. PubMed ID: 22644942
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.
Pei N; Wan R; Chen X; Li A; Zhang Y; Li J; Du H; Chen B; Wei W; Qi Y; Zhang Y; Katovich MJ; Sumners C; Zheng H; Li H
Mol Cancer Ther; 2016 Jan; 15(1):37-47. PubMed ID: 26671566
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
Soto-Pantoja DR; Menon J; Gallagher PE; Tallant EA
Mol Cancer Ther; 2009 Jun; 8(6):1676-83. PubMed ID: 19509262
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Menon J; Soto-Pantoja DR; Callahan MF; Cline JM; Ferrario CM; Tallant EA; Gallagher PE
Cancer Res; 2007 Mar; 67(6):2809-15. PubMed ID: 17363603
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
Tesan T; Gustavsson H; Welén K; Damber JE
BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
[TBL] [Abstract][Full Text] [Related]
10. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence.
Taylor AP; Rodriguez M; Adams K; Goldenberg DM; Blumenthal RD
Int J Cancer; 2003 Jun; 105(2):158-64. PubMed ID: 12673673
[TBL] [Abstract][Full Text] [Related]
11. Placental growth factor upregulation is a host response to antiangiogenic therapy.
Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
[TBL] [Abstract][Full Text] [Related]
12. Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.
Bagley RG; Ren Y; Kurtzberg L; Weber W; Bangari D; Brondyk W; Teicher BA
Int J Oncol; 2012 Feb; 40(2):479-86. PubMed ID: 22075622
[TBL] [Abstract][Full Text] [Related]
13. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
15. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
Wu Y; Hooper AT; Zhong Z; Witte L; Bohlen P; Rafii S; Hicklin DJ
Int J Cancer; 2006 Oct; 119(7):1519-29. PubMed ID: 16671089
[TBL] [Abstract][Full Text] [Related]
16. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
17. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
19. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study.
Anton L; Merrill DC; Neves LA; Gruver C; Moorefield C; Brosnihan KB
Reprod Biol Endocrinol; 2010 Nov; 8():135. PubMed ID: 21050477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
